The observation that early stage melanomas exhibit a lower prevalence of BRAF mutations than that found in late stage lesions [46,47] argues against the hypothesis that BRAF activation participates in the initiation of melanoma but seems to strongly suggest that such an alteration could be involved in disease progression. This evidence concerns the gene BRAF and melanoma.